Recent genetic studies have identified Gasdermin B (GSDMB) polymorphisms as contributors to enhanced Type-2 cytokine responses in asthma (48), underscoring potential upstream regulatory mechanisms influencing Th2 biomarkers expression and asthma remission. This evidence concerns the gene GSDMB and asthma.